230 related articles for article (PubMed ID: 15213598)
1. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma.
Vang R; Barner R; Wheeler DT; Strauss BL
Int J Gynecol Pathol; 2004 Jul; 23(3):223-33. PubMed ID: 15213598
[TBL] [Abstract][Full Text] [Related]
2. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
4. Utility of AMACR immunohistochemical staining in differentiating Arias-Stella reaction from clear cell carcinoma of ovary and endometrium.
Nili F; Sadri M; Ameli F
BMC Cancer; 2023 Apr; 23(1):332. PubMed ID: 37041497
[TBL] [Abstract][Full Text] [Related]
5. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical profile of atypical eosinophilic syncytial changes vs serous carcinoma.
Haley SL; Malhotra RK; Qiu S; Eltorky ME
Ann Diagn Pathol; 2011 Dec; 15(6):402-6. PubMed ID: 21855381
[TBL] [Abstract][Full Text] [Related]
7. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
8. Contribution of immunohistochemical profile in assessing histological grade of endometrial cancer.
Canlorbe G; Laas E; Bendifallah S; Daraï E; Ballester M
Anticancer Res; 2013 May; 33(5):2191-8. PubMed ID: 23645775
[TBL] [Abstract][Full Text] [Related]
9. Napsin A, Hepatocyte Nuclear Factor-1-Beta (HNF-1β), Estrogen and Progesterone Receptors Expression in Arias-Stella Reaction.
Ip PPC; Wang SY; Wong OGW; Chow KL; Lee HH; Cheung ANY; Tse KY
Am J Surg Pathol; 2019 Mar; 43(3):325-333. PubMed ID: 30608233
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
11. Use of Immunohistochemical Markers (HNF-1β, Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction.
Ji JX; Cochrane DR; Tessier-Cloutier B; Leung S; Cheng AS; Chow C; Gilks B; Huntsman DG; Hoang LN
Int J Gynecol Pathol; 2020 Jul; 39(4):344-353. PubMed ID: 31094885
[TBL] [Abstract][Full Text] [Related]
12. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
[TBL] [Abstract][Full Text] [Related]
13. Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2): a novel biomarker for the identification of atypical hyperplasia and Type I endometrial carcinoma.
Buell-Gutbrod R; Cavallo A; Lee N; Montag A; Gwin K
Int J Gynecol Pathol; 2015 Jan; 34(1):65-73. PubMed ID: 25473755
[TBL] [Abstract][Full Text] [Related]
14. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
15. Selected immunohistochemical prognostic factors in endometrial cancer.
Markova I; Duskova M; Lubusky M; Kudela M; Zapletalová J; Procházka M; Pilka R
Int J Gynecol Cancer; 2010 May; 20(4):576-82. PubMed ID: 20686376
[TBL] [Abstract][Full Text] [Related]
16. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
[TBL] [Abstract][Full Text] [Related]
17. The Arias-Stella reaction: facts and fancies four decades after.
Arias-Stella J
Adv Anat Pathol; 2002 Jan; 9(1):12-23. PubMed ID: 11756756
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma.
Fadare O; Liang SX
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):580-7. PubMed ID: 22495362
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein CD44 expression in normal, hyperplasic and neoplastic endometrium. An immunohistochemical study including correlations with p53, steroid receptor status and proliferative indices (PCNA, MIB1).
Zagorianakou N; Ioachim E; Mitselou A; Kitsou E; Zagorianakou P; Stefanaki S; Makrydimas G; Agnantis NJ
Eur J Gynaecol Oncol; 2003; 24(6):500-4. PubMed ID: 14658589
[TBL] [Abstract][Full Text] [Related]
20. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features.
Yu CG; Jiang XY; Li B; Gan L; Huang JF
Asian Pac J Cancer Prev; 2015; 16(15):6789-94. PubMed ID: 26434913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
